Drugs / Isotretinoin
Isotretinoin
English name isotretinoin
also known as
13- cis -Retinoic acid · Retinoic Acid · 13cis RA · Accutane · 13-CRA · Cis-Retinoic acid · ISO · Roaccutane · +6 more
Other / unclassified targets ACE2, CYP2D6, TMPRSS2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ACCUTANE | — | 1986-06-06 – 2002-05-02 | fda.gov ↗ |
| Approved | US (FDA) | ACCUTANE | — | 1982-05-07 | fda.gov ↗ |
Trials 121 · started per year
today
US approved 1982
1
1
1
1
1
3
2
3
2
10
1
1
5
4
3
7
1
5
3
5
1
1
3
4
2
4
3
3
5
7
5
5
4
8
4
1981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT06942039 | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT06225570 | Feb 2025 → Mar 2027 expected | acne | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 0 | NCT05281965 | Apr 2022 → Jun 2023 | 15q11q13 microduplication syndrome, autism spectrum disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT03491267 | Jan 2018 → Nov 2024 | central centrifugal cicatricial alopecia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT02620813 | Oct 2015 → Oct 2017 | acne | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT03392623 | Jan 2015 → Jan 2016 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT06485505 | Jul 2024 → Jul 2026 overdue | tinea unguium | Zagazig University | Recruiting | No outcome recorded |
| Phase 1 | NCT06201624 | Mar 2023 → Jan 2024 | hyperpigmentation of the skin | Zagazig University | Unknown | No outcome recorded |
| Phase 1 | NCT04382950 | Jul → Aug 2021 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 1 | NCT03611595 | Aug 2018 → Feb 2026 | cancer | Peter Zage | Completed | No outcome recorded |
| Phase 1 | NCT01711554 | Feb 2013 → Sep 2018 overdue | neuroblastoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01175356 | Dec 2011 → Sep 2016 | ganglioneuroblastoma, neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01888224 | Jun 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01319838 | Mar 2011 → Dec 2013 | neuroblastoma | Emory University | Withdrawn | No outcome recorded |
| Phase 1 | NCT01208454 | Dec 2010 → Sep 2014 | neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01103375 | May 2010 → Jan 2013 | adult glioblastoma, adult oligodendroglioma, anaplastic astrocytoma, anaplastic oligodendroglioma +3 | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT00867178 | Feb 2009 → Apr 2020 | medulloblastoma, pineoblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00533169 | Sep 2007 → Feb 2011 | neuroblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00334789 | Jun 2006 → Mar 2018 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00416585 | Oct 2005 → Nov 2006 | acne | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00217412 | Aug 2005 → Sep 2009 | Burkitt lymphoma, Hodgkins lymphoma, acute promyelocytic leukemia, atypical teratoid rhabdoid tumor +9 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005576 | Jan 2001 → Mar 2002 | neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00014729 | Oct 2000 → Sep 2002 | epidermolysis bullosa dystrophica | University of North Carolina | Completed | No outcome recorded |
| Phase 1 | NCT00000764 | ? → Jul 1996 | HIV infectious disease, anus neoplasm | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT07015931 | Nov 2024 → Mar 2025 | acne | Indonesia University | Completed | No outcome recorded |
| Phase 1/2 | NCT06020833 | Aug 2023 → Oct 2025 | myelodysplastic syndrome | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05384821 | Sep 2022 → May 2028 expected | Wilms tumor | Centre Oscar Lambret | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04730895 | Jul → Sep 2021 | — | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04594759 | Nov 2020 → Dec 2021 | acne | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT03291080 | Apr 2018 → Sep 2019 | neuroblastoma | Nova Laboratories Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT01560585 | Apr 2012 → Aug 2014 | Alzheimer disease | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00555399 | Nov 2007 → Jan 2020 | glioblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00324740 | Mar 2006 → Feb 2011 | renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00003619 | Feb 1998 → Apr 2004 | leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, thrombocytopenia | Drexel University College of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00003585 | Aug 1996 → Aug 2001 | kidney cancer | University of New Mexico | Completed | No outcome recorded |
| Phase 238 trials | ||||||
| Phase 2 | NCT07629167 | Aug 2026 → Aug 2029 expected | acneiform dermatitis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07481370 | Apr 2026 → Jun 2027 expected | azoospermia, oligospermia | University of Nebraska | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06731140 | Feb 2025 → Oct 2026 expected | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT04909515 | Dec 2021 → Jun 2026 | neuroblastoma | Y-mAbs Therapeutics | Withdrawn | No outcome recorded |
| Phase 2 | NCT05077813 | Dec 2021 → Feb 2022 | tuberculosis | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04385277 | Dec 2020 → Jun 2023 overdue | neuroblastoma, nodular ganglioneuroblastoma | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04578236 | Nov → Dec 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04154293 | Dec 2019 → Aug 2021 | inherited ichthyosis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT04870489 | Nov 2017 → Nov 2020 | acne | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03323801 | Jul 2017 → May 2019 | azoospermia | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT02864082 | Mar 2017 → Feb 2018 | inherited ichthyosis | Patagonia Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03033303 | Jan 2017 → Sep 2025 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02771743 | Apr 2015 → Mar 2020 | neuroblastoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02169609 | Nov 2014 → Dec 2016 | neuroblastoma | Fundació Sant Joan de Déu | Completed | No outcome recorded |
| Phase 2 | NCT02061384 | Aug 2014 → Dec 2018 | Klinefelter syndrome, partial chromosome Y deletion | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT01334515 | Sep 2011 → Dec 2013 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01183884 | Aug 2010 → Nov 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01048086 | Jun 2009 → Nov 2013 | neuroblastoma, neuroendocrine neoplasm | University of Iowa | Withdrawn | No outcome recorded |
| Phase 2 | NCT01276730 | Oct 2007 → Aug 2015 | cervical cancer | University of Louisville | Completed | No outcome recorded |
| Phase 2 | NCT00339196 | Jul 2006 → Jul 2008 | acute myeloid leukemia, myelodysplastic syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00528437 | Oct 2005 → Jun 2017 | brain neoplasm | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00112502 | Sep 2005 → Sep 2014 | glioblastoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00098020 | Nov 2004 → Jun 2016 | focal segmental glomerulosclerosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00089258 | Jul 2004 → Nov 2006 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00062010 | May 2004 → May 2011 | small cell lung carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00176527 | Nov 2002 → Aug 2007 | prostate cancer | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
| Phase 2 | NCT00025038 | Jun 2001 → Oct 2007 | juvenile myelomonocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005847 | Apr 2001 → Jul 2004 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00017368 | Apr 2001 → Sep 2005 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00138151 | Mar 2001 → Nov 2010 | cervical cancer | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
| Phase 2 | NCT00040872 | Jun 2000 → Jan 2007 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00000621 | Sep 1999 → Dec 2004 | pulmonary emphysema | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00021359 | Aug 1999 → Jul 2000 | plasma cell myeloma | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00004110 | Aug 1999 → Sep 2004 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003405 | Apr 1998 → Apr 1999 | leukemia | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00002586 | Jan 1993 → Dec 2005 | lung cancer, poisoning | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT00002506 | Aug 1992 → Jan 1996 | cervical cancer, esophageal cancer, head and neck cancer, lung cancer +2 | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00038376 | May 1990 → Jun 2005 | mycosis fungoides | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 321 trials | ||||||
| Phase 3 | NCT06447480 | Apr 2025 → Sep 2026 expected | acne | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 3 | NCT05295732 | Jun 2022 → Jun 2024 | ichthyosis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT05016349 | Aug → Oct 2021 | female breast carcinoma | Mahmoud Ramadan mohamed Elkazzaz | Unknown | No outcome recorded |
| Phase 3 | NCT04290572 | Mar 2020 → Feb 2023 | common wart | Centro Dermatológico Dr. Ladislao de la Pascua | Unknown | No outcome recorded |
| Phase 3 | NCT04175587 | Dec 2019 → Aug 2021 | acute promyelocytic leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01041638 | Dec 2009 → Dec 2013 | neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00975143 | Sep 2009 → May 2011 | acne | Cipher Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00499616 | Oct 2007 → Jun 2014 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00392327 | May 2007 → Jun 2019 | anaplastic/large cell medulloblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00882531 | Feb 2007 → Aug 2009 | rosacea | Laboratoires Bailleul-Biorga | Completed | No outcome recorded |
| Phase 3 | NCT00410631 | Oct 2004 → Dec 2010 | neuroblastoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| Phase 3 | NCT00078988 | Oct 2004 → Sep 2006 | brain neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00054561 | Nov 2003 → Dec 2004 | head and neck cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00030719 | Dec 2001 → ? | neuroblastoma | University of Leicester | Unknown | No outcome recorded |
| Phase 3 | NCT00026312 | Oct 2001 → Jan 2012 | neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00004188 | Feb 2001 → Oct 2007 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002737 | Mar 1996 → Jan 2001 | kidney cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT03370367 | May 1989 → Jan 1999 | head and neck carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003599 | — | lung cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT00001073 | ? → Mar 2001 | HIV infectious disease, dysplasia of cervix | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00003564 | — | central nervous system cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07675239 | Oct 2026 → Mar 2027 expected | tinea corporis | Pak Emirates Military Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07639073 | Jul → Oct 2026 expected | acne | Pakistan Institute of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06698263 | Mar 2025 → Dec 2027 expected | male infertility | University Hospital, Strasbourg, France | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07012811 | Feb 2024 → Mar 2025 | skin disorder caused by infection | Latakia University | Completed | No outcome recorded |
| Phase 4 | NCT06047535 | Oct 2023 → Jun 2027 expected | neuroblastoma | SciClone Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06873087 | Sep 2023 → Jun 2024 | rosacea | SB Istanbul Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05666765 | Jan → Nov 2023 | acne | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT05002530 | Nov → Dec 2021 | anosmia | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 4 | NCT04940767 | Jun 2021 → Apr 2023 | acne | Edward Lain, MD | Completed | No outcome recorded |
| Phase 4 | NCT04623385 | Nov → Dec 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 4 | NCT03076021 | Jul 2016 → Nov 2023 | — | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT02457520 | Jan 2015 → Apr 2018 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01445028 | Sep 2011 → Aug 2013 | proliferative vitreoretinopathy | Wills Eye | Completed | No outcome recorded |
| Phase 4 | NCT01404130 | Sep 2008 → Nov 2010 | acne | University of Aberdeen | Completed | No outcome recorded |
| Phase 4 | NCT07228481 | Jun 2001 → Mar 2025 | acne | Premier Specialists, Australia | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07142070 | Sep → Dec 2025 overdue | periodontal disorder | Medipol University | Not yet recruiting | No outcome recorded |
| — | NCT07309341 | Jun 2025 → Jul 2026 | anosmia | Uşak University | Completed | No outcome recorded |
| — | NCT07420894 | Jan → Jul 2025 | dermatophytosis | Multan Medical And Dental College | Completed | No outcome recorded |
| — | NCT07675460 | Apr 2024 → Jul 2025 | acne, dry eye syndrome | Demet Mutlu | Completed | No outcome recorded |
| — | NCT06378983 | Sep 2022 → Jun 2024 | acne | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT05622253 | Mar → Dec 2022 | acne | Zagazig University | Completed | No outcome recorded |
| — | NCT04204304 | Mar → Aug 2019 | isotretinoin syndrome, musculoskeletal system disorder, vitamin D deficiency | Ankara Training and Research Hospital | Completed | No outcome recorded |
| — | NCT02795143 | Nov 2016 → Jun 2020 | toxic epidermal necrolysis | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| — | NCT02100930 | Mar 2014 → Mar 2019 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00939965 | Feb 2009 → ? | neuroblastoma | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| — | NCT00526318 | Jan 2007 → Dec 2016 | neuroblastoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| — | NCT00025012 | Jun 1991 → Feb 2004 | cutaneous melanoma | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 49 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05373901 Background | Jun 2022 → Jun 2023 | neuroblastoma | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT00098891 Background | Oct 2004 → Mar 2008 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +13 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00070200 Background | Mar 2004 → Sep 2006 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01020539 Background | Sep 2002 → Jul 2011 | acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome | Columbia University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01592045 Background | Aug 2012 → Jun 2014 | neuroblastoma | United Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01701479 Background | Jan 2012 → Dec 2020 | neuroblastoma | St. Anna Children's Cancer Research | Unknown | No outcome recorded |
| Phase 1/2 | NCT00609739 Background | Jun 1999 → Jun 2010 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT05684861 Comparator | Jan → Dec 2022 | acne | South Valley University | Completed | No outcome recorded |
| Phase 2 | NCT05119413 Background | Nov 2021 → Sep 2022 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 2 | NCT04389580 Comparator | Sep → Oct 2021 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04577378 Comparator | Oct → Nov 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04396067 Comparator | Oct 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT03471455 Comparator | Apr 2018 → Jan 2019 | tinea infection | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 2 | NCT02641782 Background | Nov 2015 → Dec 2016 | neuroblastoma | University of Cologne | Terminated | No outcome recorded |
| Phase 2 | NCT01969058 Comparator | Jul 2014 → Aug 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01857934 Background | Jul 2013 → Oct 2021 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02278861 Comparator | Nov 2011 → Apr 2014 | actinic keratosis | Federal University of Goiás | Completed | No outcome recorded |
| Phase 2 | NCT01183429 Background | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01183897 Background | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01183416 Background | Aug 2010 → Oct 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00969722 Comparator | Aug 2009 → Aug 2010 | neuroblastoma | United Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT00842907 Comparator | May → Dec 2009 | radiation-induced disorder | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT00808899 Background | Dec 2008 → Jul 2009 | neuroblastoma | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00701740 Comparator | Jul 2007 → Jan 2008 | — | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT00200161 Background | Aug 2005 → May 2017 | glioblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00135135 Background | Aug 2005 → Jun 2007 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06172296 Background | Apr 2024 → Dec 2029 expected | neuroblastoma, nodular ganglioneuroblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06242288 Comparator | Jan 2024 → Jan 2025 | acne | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 3 | NCT04353180 Comparator | Aug → Oct 2021 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 3 | NCT04361422 Comparator | Dec 2020 → Aug 2021 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT03126916 Background | May 2018 → Sep 2030 expected | neuroblastoma, nodular ganglioneuroblastoma | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06451237 Comparator | Jan 2018 → Dec 2022 | acne | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT01474590 Comparator | Nov 2011 → Jul 2013 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00567567 Background | Nov 2007 → Feb 2015 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT03042429 Comparator | Jan 2007 → Dec 2016 | neuroblastoma | University of Cologne | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07676994 Comparator | May → Dec 2025 | hyperpigmentation of the skin | Ghurki Trust and Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05316675 Comparator | Dec 2022 → Oct 2024 | acne | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04864717 Comparator | Sep 2021 → Dec 2022 | acneiform dermatitis, cancer-related condition | Lady Davis Institute | Unknown | No outcome recorded |
| Phase 4 | NCT05218486 Comparator | Aug 2021 → Sep 2022 | acne | Alshimaa Abbas Mohamed Ebrahim | Unknown | No outcome recorded |
| Phase 4 | NCT05529888 Comparator | Dec 2020 → Dec 2021 | acne | Aswan University | Completed | No outcome recorded |
| Phase 4 | NCT02855138 Comparator | Jan 2015 → Mar 2016 | — | Kayseri Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01139749 Comparator | Oct 2011 → Jul 2012 | seborrheic dermatitis | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00863278 Comparator | Mar 2009 → Mar 2010 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Terminated | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07054398 Comparator | Jan 2025 → Jan 2026 overdue | acne | Aswan University | Recruiting | No outcome recorded |
| — | NCT05869188 Comparator | Jun → Dec 2023 | acne | South Valley University | Completed | No outcome recorded |
| — | NCT04167982 Comparator | Mar 2020 → Nov 2022 | acne | Shanghai Dermatology Hospital | Unknown | No outcome recorded |
| — | NCT04417348 Comparator | Jan → Sep 2019 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| — | NCT03514771 Background | Jan 2016 → Mar 2017 | mixed dermis disorder | David Smart | Completed | No outcome recorded |
| — | NCT01526603 Background | Mar 2012 → May 2023 | neuroblastoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 174 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | isotretinoin | “In another study by Sinha et al who analyzed a publicly available Connectivity Map (CMAP) dataset of pre/post transcriptomic profiles for drug treatment in cell lines for over...” NCT04382950 ↗128“After searching, we found a study analyzed a broad set of 672 clinically approved drugs for treatment in cell lines demonstrated that isotretinoin was the potent and strongest...” NCT04730895 ↗ “Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First...” NCT06047535 ↗ “Seconed drug is Isotretinoin(13cis RA) and ATRA may be able to inhibit COVID 2019 infection via inducing the antiviral immunity and this is discussed as follow :” NCT04396067 ↗ “Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin” NCT03042429 ↗ “Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if \< 12kg) PO divided into 2 doses daily x 14 days.” NCT02169609 ↗ “Isotretinoin remains the mainstay of acne treatment.” NCT05622253 ↗ “Post-transplantation isotretinoin therapy” NCT00609739 ↗ “isotretinoin” NCT00701740 ↗ |
| Known as | 13- cis -Retinoic acid | “Subsequently, however, a sentinel randomized clinical trial demonstrated that isotretinoin(13-cis-retinoic acid), when given to patients with minimal residual disease following...” NCT01319838 ↗44“Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ “Isotretinoin (13-cis retinoic acid; 13-cis RA) is the only drug capable of inducing a long-term or permanent remission of acne; however, the mechanisms leading to this durable...” NCT04396067 ↗ “The most effective treatment for acne is still isotretinoin (13-cis-retinoic acid), an oral retinoid that was licensed in 1982 for the treatment of acne vulgaris.” NCT07054398 ↗ “Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne” NCT06242288 ↗ “Oral isotretinoin (13-cis-retinoic acid) is the only drug that counteracts all the pathogenetic mechanisms that contribute to the development of acne” NCT05529888 ↗ “Oral isotretinoin (13-cis-retinoic acid) is the only drug that counteracts all the pathogenetic mechanisms that contribute to the development of acne” NCT05218486 ↗ “Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.” NCT03076021 ↗ “13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy” NCT01276730 ↗ “A study demonstrated that 13- cis -Retinoic acid competitively and reversibly inhibits dihydrotestosterone.” NCT04623385 ↗ “A study demonstrated that 13- cis -Retinoic acid competitively and reversibly inhibits dihydrotestosterone.” NCT04578236 ↗ “Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:” NCT01592045 ↗ “isotretinoin (13-cis retinoic acid) is the most potent known inhibitor of sebum production.” NCT05869188 ↗ “Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules.” NCT04940767 ↗ “13-cis-retinoic acid 160 mg/m2/day divided into two equal doses given orally BID x 14 days” NCT00135135 ↗ “13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols.” PMID 33919763 ↗ Apr 2021 “controlled prospective study of oral isotretinoin (also called 13-cis retinoic acid)” PMID 3287161 ↗ Jun 1988 “The study design is an open-label trial of isotretinoin (13-cis retinoic acid).” NCT00098020 ↗ “Isotretinoin (13-cis retinoic acid) is a synthetic analog of vitamin A.” NCT05684861 ↗ “13-cis-retinoic acid is started no later than after cycle 4” NCT01183897 ↗ “isotretinoin 13-cis-retinoic acid), derived from vitamin A” NCT05316675 ↗ “13-cis Retinoic Acid (Isotretinoin) and Sperm Production” NCT06698263 ↗ “Isotretinoin(Aerosolized 13 cis retinoic acid)” NCT04577378 ↗ “Isotretinoin (13-cis-retinoic acid)” NCT01526603 ↗ “Isotretinoin (13-cis-retinoic acid)” NCT07675460 ↗ |
| Known as | 13-CRA | “Isotretinoin, 13-CRA, NSC-329481; with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗1“13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols.” PMID 33919763 ↗ Apr 2021 |
| Known as | 13cis RA | “We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without alpha tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled...” PMID 19401528 ↗ Apr 20095“Seconed drug is Isotretinoin(13cis RA) and ATRA may be able to inhibit COVID 2019 infection via inducing the antiviral immunity and this is discussed as follow :” NCT04396067 ↗ “Isotretinoin(13cis RA) may be able to inhibit COVID 2019 infection via reversIing the androgenic induction and activation effect of (DHT) on TMPRSS2 expression” NCT04353180 ↗ “Isotretinoin(13cis RA) may be able to inhibit COVID 2019 entry via down regulation of ACE2 via action like shRNA targeting ACE2 gene expression” NCT04382950 ↗ “Isotretinoin (13-cis retinoic acid (13-cis RA)) is the most potent inhibitor of sebum production” PMID 16575387 ↗ Mar 2006 “Isotretinoin(13cis RA) may be able to inhibit COVID 2019 entry via down regulation of ACE2” NCT04389580 ↗ |
| Known as | Accutane | “Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under...” NCT04940767 ↗4“Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne” NCT06242288 ↗ “Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug” NCT04577378 ↗ “conventional course of isotretinoin (formerly known as Accutane)” NCT04594759 ↗ “Isotretinoin (Accutane)” NCT00038376 ↗ |
| Known as | CIP-Isotretinoin | “The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily...” NCT00975143 ↗ |
| Known as | Cis-Retinoic acid | “Maintenance cis-retinoic acid.” NCT00200161 ↗ |
| Known as | cRA | “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ |
| Known as | ISO | “Isotretinoin (ISO) has been used in the treatment of patients with severe acne vulgaris (AV)” NCT04204304 ↗1“Oral isotretinoin (ISO) is the gold standard for severe nodular acne.” PMID 24934963 ↗ Oct 2014 |
| Known as | NSC-329481 | “Isotretinoin, 13-CRA, NSC-329481; with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ |
| Known as | PAT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864082 ↗ |
| Known as | Retinoic Acid | “BACKGROUND: Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma.” PMID 37620285 ↗ Sep 202315“New trio combination is a drug containing 0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid and 0.1% dexamethasone” NCT07676994 ↗ “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ “The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.” NCT00863278 ↗ |
| Known as | Roaccutane | “Oral administration of isotretinoin (Roaccutane) in capsule form” NCT07228481 ↗1“isotretinoin (Roaccutane)” NCT00416585 ↗ |
| Known as | TMB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05295732 ↗ |
| Known as | Vesanoid | “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ |
| Action | Activate | “They act through binding to and activating specific nuclear receptors” NCT00339196 ↗ |
| Modality | Small molecule | “Retinoids represent a large group of compounds structurally related to vitamin A (retinol)” NCT00339196 ↗ |
| Route | Oral | “Patients are randomized to receive oral isotretinoin for 6 months or be observed only for 6 months” NCT00001073 ↗ |
| Target | CYP2D6 | “Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.” NCT03076021 ↗ |